177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01653-2/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_infocusoncology_esmo24&_hsenc=p2ANqtz-8VLKqnXWq3LNZ1XQb82vsfIxE553dX8M2PDAAMsPds5n2nqPu9a-B2ccpykBUlr2a_GDX1PyMGx3-x2lW_4CjGJr81Kw&_hsmi=325179166&utm_content=325179166&utm_source=hs_email